![PDF) Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC PDF) Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC](https://i1.rgstatic.net/publication/348874697_Old_but_gold_the_role_of_drug_combinations_in_improving_response_to_immune_check-point_inhibitors_in_thoracic_malignancies_beyond_NSCLC/links/601ac1a745851589397d54a6/largepreview.png)
PDF) Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC
![PDF) Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC PDF) Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC](https://www.researchgate.net/profile/Luca-Cantini-2/publication/348874697/figure/fig1/AS:987149855883265@1612366274135/Immune-modulation-of-tumor-microenvironment-mediated-by-main-drugs-platinum-based_Q320.jpg)
PDF) Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC
![Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial - The Lancet Oncology Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/0ec59ff3-8b98-4c3d-bf8c-bb6f1c6d1ed1/gr3_lrg.gif)
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial - The Lancet Oncology
![Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial - The Lancet Oncology Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/f8480e9b-a757-468d-9750-713e4a6ce845/gr1.gif)